Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

31results about How to "Facilitate their formulation" patented technology

Coverage analysis of message flows

A method for assessing adequacy of message flow testing, including defining coverage criteria for testing a message flow through a set of message flow elements, determining a message-flow-coverage-goal for the message flow with respect to the coverage criteria, and designing a test suite responsive to the message-flow-coverage-goal. The method further includes applying the test suite to the message flow to generate a coverage result for the set of message flow elements and comparing the coverage result with the message-flow-coverage-goal.
Owner:IBM CORP

Amido-organoborate initiator systems

In one embodiment, the invention is a system for initiating free radical polymerization comprising: a) in one part, one or more amido-borate compounds containing one or more anionic amido-borate moieties comprising an organoborate wherein the boron atom is bonded to a nitrogen atom of ammonia or an organic compound containing one or more nitrogen atoms, such as a hydrocarbyl amine, a hydrocarbyl polyamine, or an aromatic heterocycle containing one or more nitrogen atoms and optionally containing one or more heteroatoms or heteroatom containing functional moieties, and one or more cationic counter ions and b) in a second part, a liberating compound which reacts with the nitrogen atom(s) bound to the boron atom(s) upon contact with the amido-borate to form an organoborane radical. In another embodiment, the invention is a two part polymerizable composition comprising in one part, one or more amido-borate compounds and in the second part, a liberating compound which reacts with the nitrogen atoms bound to the boron atom upon contact with the amido-borate to form an organoborane radical and one or more compounds capable of free radical polymerization. The first part may further comprise one or more compounds capable of free radical polymerization. This facilitates formulating compositions that have commercially desirable volumetric ratios of the two parts.
Owner:DOW GLOBAL TECH LLC

Accelerated organoborane initiated polymerizable compositions

The invention is a two part polymerizable composition comprising in one part an organoboron compound capable of forming free radical generating species and in the second part one or more compounds capable of free radical polymerization and from about 20 to about 30 parts by weight based on the weight of the second part of i) a halogenated polyolefin having halosulfonyl groups or ii) a mixture of a halogenated polyolefin and an organic sulfonyl halide. The second part may further contain a compound capable of causing the organoboron compound to form free radical generating species upon contacting the two parts. The first part may further comprise one or more compounds capable of free radical polymerization.
Owner:DOW GLOBAL TECH LLC

Biocidal Colloidal Dispersions of Silica Particles with Silver Ions Adsorbed Thereon

ActiveUS20120301553A1High bactericidal activityExcellent non-leachability of nano-particlesMaterial nanotechnologyPigmenting treatmentIonAluminium silicate
A colloidal dispersion having carrier particles of silica having a particle size from 3 nm to 100 nm to which silver ions have been adsorbed, preferably in an amount of 0.0005-5 silver ions per nm2 of silica particle surface. The surface of the carrier particles of silica suitably contains aluminumsilicate sites. It also relates to a process for making a colloidal dispersion comprising providing a silica sol, adding a solution of silver nitrate to the silica sol under agitation yielding a colloidal dispersion with silver ions adsorbed on the surface of the silica particles. The dispersion is usable as a biocide in e.g. coatings, adhesives and sealants, in surface treatment and impregnation of organic materials, in surface treatment and impregnation of inorganic materials, in textiles, garments and shoes, in medical disposables, in plastics and rubbers, in water and air purification, and in crop protection.
Owner:PREBONA

Salicylic Acid Composition

Provided, among other things, is a delivery module for water-based salicylic acid composition comprising: an aerosol delivery system; within the aerosol delivery system, the salicylic acid composition comprising 0.5% or more salicylic acid by weight, lipophilic component(s), and a frothing agent, the salicylic acid composition having a viscosity low enough to support aerosol delivery, and the salicylic acid composition effective to form a foam upon propellant-driven aerosol delivery; and within the aerosol delivery system, a propellant, wherein the salicylic acid composition is non-irritating and has a non-watery feel.
Owner:EXELTIS USA DERMATOLOGY

Wt1 antigen peptide conjugate vaccine

ActiveUS20150080321A1Efficiently induceEfficiently convertTumor rejection antigen precursorsPeptide/protein ingredientsAntigenChemistry
A compound represented by the formula (1):wherein Xa and Ya are each a single bond and the like, cancer antigen peptide A is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, R1 is a hydrogen atom, a group represented by the formula (2):wherein Xb and Yb are each a single bond and the like, cancer antigen peptide B has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, or cancer antigen peptide C, and cancer antigen peptide C has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide or an MHC class II-restricted WT1 peptide, consisting of 7-30 amino acid residues containing one cysteine residue, or a salt thereof, and the like.
Owner:INT INST OF CANCER IMMUNOLOGY INC

Individual impedance-based radio-frequency heating temperature field prediction method and system

The present application relates to the field of biomedical engineering. Disclosed are an individual impedance-based radio-frequency heating temperature field prediction method and system which greatly improve the rate and accuracy of temperature distribution prediction. The method of the present application comprises: creating a first region; obtaining a position of an ablation needle, and with the ablation needle as a center, creating a second region in the first region; keeping the electrical conductivity within the second region constant, and adjusting the electrical conductivity in the first region such that impedance between the ablation needle and an earth pole is consistent with real individual impedance actually measured by a treatment system; performing mesh division on a combination of the first region and the second region and performing coupling computation using a radio-frequency field model and a biological heat transfer model to obtain temperature field time-space information.
Owner:MAGI CO LTD

Oligosaccharide compound for inhibiting intrinsic coagulation factor x-enzyme complex, and preparation method therefor and uses thereof

A purified oligosaccharide compound having antithrombotic activity or a mixture of a homologous compound thereof and a pharmaceutically acceptable salt thereof, a preparation method for the mixture, a pharmaceutical composition containing the mixture, and uses thereof serving as an intrinsic factor X-enzyme (Xase) inhibitor in the preparation of drugs for preventing and / or treating thrombotic diseases.
Owner:JIUZHITANG +1

Pharmaceutical Formulation with Improved Solubility and Bioavailability

The present invention relates to a pharmaceutical formulation comprising at least one active pharmaceutical ingredient (API) having low aqueous solubility or a pharmaceutically acceptable salt thereof in the form of particles of a size between 1 and 800 nm, wherein said particles are encapsulated within a large microparticle of a size between 1 and 100 μm formed by a matrix comprising at least an excipient. Therefore, the API is entrapped or encapsulated in the microparticles of excipients. This pharmaceutical formulation contains the pharmaceutical active ingredient having improved solubility and subsequently supra-bioavailability.
Owner:CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) +2
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products